Imatinib used in CML acts by –
Correct Answer: Competitive inhibition ofATP binding site ofABL kinase
Description: Ans. is 'c' i.e. Competitive inhibition of ATP binding site of ABL kinase o In CML, there is Bcr-Abl translocation which leads to unregulated activation of intracellular (non-receptor) tyrosine kinase, Le., Bcr-Abl tyrosine kinase. o Imatinib is a Bcr-Abl tyrosine kinase (intracellular-nonreceptor tyrosine kinase) inhibitor. o This drug block the activity of nonreceptor tyrosine kinase by acting as a inhibitor of the ATP binding site on the protein and prevents its phosphorylation. About option 'a' o Imatinib does not inhibit Bcr-Abl translocation, it inhibits overactive tyrosine kinase after Bcr-Abl translocation has already occured.
Category:
Pharmacology
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now